BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22759273)

  • 1. Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer.
    Iqbal J; Thike AA; Cheok PY; Tse GM; Tan PH
    Histopathology; 2012 Oct; 61(4):652-9. PubMed ID: 22759273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer.
    Wang J; Zhang C; Chen K; Tang H; Tang J; Song C; Xie X
    Breast Cancer Res Treat; 2015 Jul; 152(2):255-69. PubMed ID: 26070269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of vitamin D receptor and insulin-like growth factor receptor 1 expression in triple-negative breast cancer.
    Soljic M; Mrklic I; Tomic S; Omrcen T; Sutalo N; Bevanda M; Vrdoljak E
    J Clin Pathol; 2018 Jan; 71(1):34-39. PubMed ID: 28663327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence?
    Colakoglu T; Yildirim S; Kayaselcuk F; Nursal TZ; Ezer A; Noyan T; Karakayali H; Haberal M
    Am J Surg; 2008 Jun; 195(6):719-25. PubMed ID: 18440486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer.
    Beg S; Siraj AK; Prabhakaran S; Jehan Z; Ajarim D; Al-Dayel F; Tulbah A; Al-Kuraya KS
    Breast Cancer Res Treat; 2015 Jun; 151(3):541-53. PubMed ID: 25981902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery.
    Breen KJ; O'Neill A; Murphy L; Fan Y; Boyce S; Fitzgerald N; Dorris E; Brady L; Finn SP; Hayes BD; Treacy A; Barrett C; Aziz MA; Kay EW; Fitzpatrick JM; Watson RWG
    Prostate; 2017 Sep; 77(12):1288-1300. PubMed ID: 28726241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer].
    Qiao YH; Cheng J; Guo RX
    Zhonghua Fu Chan Ke Za Zhi; 2007 May; 42(5):325-9. PubMed ID: 17673045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
    Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
    Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome.
    Panigrahi AR; Pinder SE; Chan SY; Paish EC; Robertson JF; Ellis IO
    J Pathol; 2004 Sep; 204(1):93-100. PubMed ID: 15307142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma.
    Capodanno A; Camerini A; Orlandini C; Baldini E; Resta ML; Bevilacqua G; Collecchi P
    Hum Pathol; 2009 Oct; 40(10):1408-17. PubMed ID: 19428048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer.
    Lim WT; Zhang WH; Miller CR; Watters JW; Gao F; Viswanathan A; Govindan R; McLeod HL
    Oncol Rep; 2007 Apr; 17(4):853-7. PubMed ID: 17342327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
    Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
    Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer.
    Yeong J; Lim JCT; Lee B; Li H; Chia N; Ong CCH; Lye WK; Putti TC; Dent R; Lim E; Thike AA; Tan PH; Iqbal J
    Front Immunol; 2018; 9():1209. PubMed ID: 29899747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.
    Bahhnassy A; Mohanad M; Shaarawy S; Ismail MF; El-Bastawisy A; Ashmawy AM; Zekri AR
    Mol Med Rep; 2015 Jul; 12(1):851-64. PubMed ID: 25824321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
    Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
    J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer.
    Thike AA; Yong-Zheng Chong L; Cheok PY; Li HH; Wai-Cheong Yip G; Huat Bay B; Tse GM; Iqbal J; Tan PH
    Mod Pathol; 2014 Mar; 27(3):352-60. PubMed ID: 23929266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
    Thike AA; Tan PH; Ikeda M; Iqbal J
    Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women.
    Khan F; Esnakula A; Ricks-Santi LJ; Zafar R; Kanaan Y; Naab T
    Pathol Res Pract; 2018 May; 214(5):673-678. PubMed ID: 29653745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation.
    Bedolla R; Prihoda TJ; Kreisberg JI; Malik SN; Krishnegowda NK; Troyer DA; Ghosh PM
    Clin Cancer Res; 2007 Jul; 13(13):3860-7. PubMed ID: 17606718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.